Literature DB >> 26335089

The effect of financial incentives on adherence to antipsychotic depot medication: does it change over time?

Hana Pavlickova1, Stephen A Bremner, Stefan Priebe.   

Abstract

OBJECTIVE: A recent cluster-randomized controlled trial found that offering financial incentives improves adherence to long-acting injectable antipsychotics (LAIs). The present study investigates whether the impact of incentives diminishes over time and whether the improvement in adherence is linked to the amount of incentives offered.
METHOD: Seventy-three teams with 141 patients with psychotic disorders (using ICD-10) were randomized to the intervention or control group. Over 1 year, patients in the intervention group received £15 (US $23) for each LAI, while control patients received treatment as usual. Adherence levels, ie, the percentage of prescribed LAIs that were received, were calculated for quarterly intervals. The amount of incentives offered was calculated from the treatment cycle at baseline. Multilevel models were used to examine the time course of the effect of incentives and the effect of the amount of incentives offered on adherence.
RESULTS: Adherence increased in both the intervention and the control group over time by an average of 4.2% per quarterly interval (95% CI, 2.8%-5.6%; P < .001). Despite this general increase, adherence in the intervention group remained improved compared to the control group by between 11% and 14% per quarterly interval. There was no interaction effect between time and treatment group. Further, a higher total amount of incentives was associated with poorer adherence (βbootstrapped = -0.11; 95% CIbootstrapped, -0.20 to -0.01; P = .023).
CONCLUSIONS: A substantial effect of financial incentives on adherence to LAIs occurs within the first 3 months of the intervention and is sustained over 1 year. A higher total amount of incentives does not increase the effect. TRIAL REGISTRATION: ISRCTN.com identifier: ISRCTN77769281 and UKCRN.org identifier: 7033. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26335089     DOI: 10.4088/JCP.14m09669

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Medication nonadherence in bipolar disorder: a narrative review.

Authors:  Ibrahim Jawad; Stuart Watson; Peter M Haddad; Peter S Talbot; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-16

2.  Can incentives improve antipsychotic adherence in major mental illness? A mixed-methods systematic review.

Authors:  Nathan Hodson; Madiha Majid; Ivo Vlaev; Swaran Preet Singh
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

3.  Treatment compliance and noncompliance in psychoses.

Authors:  K Nagaraja Rao; Jitty George; C Y Sudarshan; Shamshad Begum
Journal:  Indian J Psychiatry       Date:  2017 Jan-Mar       Impact factor: 1.759

4.  Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing.

Authors:  Marcel Bilger; Tina T Wong; Kaye L Howard; Jia Yi Lee; Ai Nee Toh; Geraldine John; Ecosse L Lamoureux; Eric A Finkelstein
Journal:  Trials       Date:  2016-07-15       Impact factor: 2.279

5.  Discontinuing financial incentives for adherence to antipsychotic depot medication: long-term outcomes of a cluster randomised controlled trial.

Authors:  Stefan Priebe; Stephen A Bremner; Hana Pavlickova
Journal:  BMJ Open       Date:  2016-09-21       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.